Literature DB >> 3162685

Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6).

G Bergamaschi1, M Cazzola, L Dezza, E Savino, L Consonni, D Lappi.   

Abstract

Cellular iron uptake is mediated by binding of transferrin with specific surface receptors and internalization of the Fe-transferrin-receptor complex. This has been examined as a possible pathway for carrying into leukaemic cells a ribosome-inactivating protein (RIP), SO-6, derived from Saponaria officinalis. Purified human differic transferrin was conjugated with SO-6 and a pool of proteins was obtained, with variable numbers of SO-6 molecules linked to a single transferrin molecule. Human erythroleukaemic K562 cells were grown in the presence of human transferrin, SO-6 and human transferrin conjugated with SO-6. The conjugate was found to be internalized via binding with transferrin receptor. Whereas the presence of unconjugated human transferrin and SO-6 in the medium did not significantly influence K562 cell growth, the conjugated proteins displayed an inhibitory activity on cell proliferation. This was maximal after 72 h at a transferrin concentration of 10(-9) M, with about 50% of cells being killed. Bovine transferrin, present in fetal calf serum, did not appear to compete with human diferric transferrin in binding to K562 cells in suspension culture. In a clonogenic assay, colony formation by leukaemic cells was not influenced by free SO-6 or transferrin, whereas the conjugated proteins were markedly inhibitory (about 100% at 10(-9) M). Our findings indicate that SO-6 can be efficiently carried into mammalian cells via the transferrin-transferrin receptor cycle and exert its ribosome inactivating activity. This is in keeping with the existence of an alternative pathway of transferrin endocytosis in addition to the classic acidic endosome pathway. From a practical viewpoint, conjugates between transferrin and SO-6 can be useful tools for studying the expression of transferrin receptors, and deserve also to be investigated for a possible use in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162685     DOI: 10.1111/j.1365-2141.1988.tb04218.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Vascular smooth cell proliferation in perfusion culture of porcine carotid arteries.

Authors:  Dan Liao; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Biochem Biophys Res Commun       Date:  2008-06-02       Impact factor: 3.575

Review 2.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

Review 3.  Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.

Authors:  Stephanie Tortorella; Tom C Karagiannis
Journal:  J Membr Biol       Date:  2014-02-27       Impact factor: 1.843

Review 4.  Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Manuela Pedrazzi; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2011-06-22       Impact factor: 4.546

5.  Intracellular metabolism and cytotoxicity of transferrin-neocarzinostatin conjugates of differing molar ratios.

Authors:  K Sasaki; Y Kohgo; J Kato; H Kondo; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1993-02

Review 6.  Targeting Receptors on Cancer Cells with Protein Toxins.

Authors:  Antonella Antignani; Eric Chun Hei Ho; Maria Teresa Bilotta; Rong Qiu; Robert Sarnvosky; David J FitzGerald
Journal:  Biomolecules       Date:  2020-09-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.